Cyril Y. Bowers

Last updated

Cyril Y. Bowers, M.D., emeritus professor of medicine at Tulane University School of Medicine, attended medical school at the University of Oregon and did an internship at the University of Washington. He then studied biochemistry at Cornell University and attended the postgraduate school of medicine at the University of Pennsylvania. From 1961-2004 he was the director of the Section of Endocrinology & Metabolism in the department of medicine at Tulane University School of Medicine. Bowers has served on the editorial board of several endocrine journals, was a member of the National Institute of Diabetes and Digestive and Kidney Diseases Study Section for eight years and has written over 400 articles in peer-reviewed journals, including chapters in books and over 200 abstracts.

Contents

Research interests

Some noteworthy accomplishments include the development of TRH analogs, LHRH antagonists and the development of a new class of small synthetic peptides (GHRPs, growth hormone releasing peptides) that specifically release growth hormone in animals and humans. In 1969, the Van Meter Award was given to Drs. Bowers, Schally and Folkers for the isolation and identification of TRH. The work on TRH strongly supported that additional hypothalamic releasing hormones would be discovered which was accomplished within the next 2 years with the discovery of LHRH by Dr. Schally’s group and others followed in subsequent years. In 1998 he received the Monsanto Clinical Investigator Award from the Endocrine Society in recognition of his contribution in the field of hypothalamic hormones and his discovery of the GHRP pathway and its clinical and therapeutic importance.

Some of Dr. Bowers’ current and future objectives include development of 1) ghrelin receptor agonists for undernutrition, i.e., cancer, cachexia, starvation; 2) ghrelin receptor antagonists for overnutrition, i.e., obesity; 3) use of ghrelin agonists in diabetes; 4) use of ghrelin agonists to restore normal function of the GH-IGF-I axis in older men and women; 5) intranasal and long acting delivery systems for ghrelin agonists/antagonists, and to obtain licenses and funds for development of the ghrelin agonists/antagonists as well as for a completed Phase I LHRH antagonist.

Selected publications

(Publications selected from over 450 peer-reviewed publications)

1. Mericq V, Cassorla F, Garcia H, Avila A, Bowers CY, Merriam G. Growth Hormone Responses to Growth Hormone Releasing Peptide (GHRP) and to Growth Hormone Releasing Hormone (GHRH) in Growth Hormone Deficient Children (GHD). J Clin Endocrinol Metab 1995; 80:1681-4.

2. Pihoker C, Middleton R, Reynolds GA, Bowers CY, Badger TM. Diagnostic Studies with Intravenous and Intranasal Growth Hormone Releasing Peptide-2 in Children of Short Stature. J Clin Endocrinol Metab 1995; 80:2987-92.

3. Van den Berghe G, de Zegher F, Veldhuis JD, Wouters P, Awouters M, Verbruggen W, Schetz M, Verwaest C, Lauwers P, Bouillon R, Bowers CY. The Somatotropic Axis in Critical Illness: Effect of Continuous GHRH and GHRP-2 Infusion. J Clin Endocrinol Metab 1997; 82:590-99.

4. Pihoker C, Badger TM, Reynolds, GA, Bowers CY. Treatment Effects of Intranasal Growth Hormone Releasing Peptide-2 in Children with Short Stature. J Endocrinol 1997; 155:79-86

5. Van den Berghe G, Veldhuis JD, de Zegher F, Wouters P, Bowers CY, Bouillon R. Growth Hormone Releasing Peptide 2 Infusion Synchronizes Growth Hormone, Thyrotropin and Prolactin Secretion in Prolonged Critical Illness. J Clin Endocrinol Metab 1997; 47:599-612.

6. Pihoker C, Kearns GL, French D, Bowers CY. Pharmacokinetics and Pharmacodynamics of Growth Hormone Releasing Peptide-2: A Phase I Study in Children J Clin Endocrinol Metab 1998; 83:1168-72.

7. Van den Berghe G, de Zegher F, Baxter RC, Veldhuis JD, Wouters P, Schetz M, Verwaest C, Van der Vorst E, Lauwers P, Bouillon R, Bowers CY. Neuroendocrinology of Prolonged Critical Illness: Effects of Exogenous Thyrotropin Releasing Hormone and Its Combination with Growth Hormone Secretagogues. J Clin Endocrinol Metab 1998; 83:309-19.

8. Bowers CY. Synergistic Release of GH by GHRP and GHRH: Scope and Implication. In B Bercu, R Walker (ed) Growth Hormone Secretagogues. Marcel Dekker, Inc New York, p. 1-25 1998.

9. Mericq V, Cassorla F, Salazar T, Avila A, Iniguez G, Bowers CY, Merriam GR. Effects of Eight Months Treatment with Graded Doses of a GH-Releasing Peptide in GH-Deficient Children. J Clin Endocrinol Metab 1998; 83:2355-2360

10. Bowers, CY. Growth Hormone Releasing Peptide (GHRP). Cell and Mol Life Sci 1998; 54(12):1316-29.

11. Van den Berghe G, Wouters P, Weekers F, Mohan S, Baxter RC, Veldhuis JD, Bowers CY, Bouillon R. Reactivation of Pituitary Hormone Release and Metabolic Improvement by Infusion of Growth Hormone Releasing Peptide and Thyrotropin Releasing Hormone in Patients with Protracted Critical Illness. J Clin Endocrinol Metab 1999; 84:2140-50.

12. Meacham LR, Culler FL, Abdul-Latif H, Sullivan KM, Bowers CY. Preservation of Growth Hormone Releasing Peptide-2 During Prednisone Therapy Metabolism 1999; 48(5):585-89.

13. Bowers CY. GH Releasing Peptides (GHRPs). In: Handbook of Physiology, Kostyo J, Goodman H, eds, Oxford University Press, New York, 1999; pg 267-297.

14. Bowers CY. GHRP Historical Perspective Basic and Clinical. In: Human Growth Hormone Basic and Clinical Research. Contemporary Endocrinology, eds R. Smith, M. Conn, Humana Press, New York, pg 17-43, 2000.

15. Bowers CY. Unnatural GHRP Begets Natural Ghrelin. J Clin Endocrinol Metab 2001; 86:1464-1469.

16. Gondo RG, Aguiar-Oliveira MH, Hayashida CY, Toledo S, Abelin N, Levine MA, Bowers CY, Souza A, Pereira R, Santos N, Salvatori R. Growth Hormone (GH) Releasing Peptide-2 Stimulates GH Secretion in GH Deficient Patients with Mutated GH-Releasing Hormone Receptor. J Clin Endocrinol Metab 2001; 86:3279-83.

17. Van den Berghe G, Baxter RC, Weekers F, Woeters P, Bowers CY, Iranmanesh A, Veldhuis JD, Bouillon R. The combined administration of GHRP-2, TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP-2 alone. Clin Endo 2002; 56:655-669.

18. Tannenbaum GA, Epelbaum J, Bowers CY. Interaction between the Novel Peptide Ghrelin and Somatostatin/GHRH in Regulation of Pulsatile GH Secretion. Endocrinology 2003; 967-974.

19. Mericq V, Cassorla F, Bowers CY, Avila A, Gonen B, Merriam G. Changes in Appetite and Body Weight in Response to Long Term Oral Administration of the Ghrelin Agonist GHRP-2 in GH Deficient Children. J Pediatric Endocrinol Metab 2003; 16:981-985.

20. Bowers CY. Historical Milestones. In: Ghrelin, Ghigo E, ed, Klerwer Academic Publishers, Boston/London; 2004, pg 1-13.

21. Iranmanesh A, Bowers CY, Veldhuis JD. Activation of Somatostatin-Receptor Subtype (SSTR)-2/5 Suppresses the Mass, Frequency and Irregularity of GHRP-2 Growth Hormone Secretion in Men. J Clin Endocrinol Metab 2004; 89:4581-87.

22. Inui A, Asakawa A, Bowers CY, Mantovani G, Laviano A, Meguid M, Fujimiya M. Ghrelin, Appetite, and Growth-The Emerging Role of the Stomach as an Endocrine Organ. FASEB J 2004; 18:439-456.

23. Bowers CY, Granda-Ayala R, Mohan S, Kuipers J, Baylink D, Veldhuis JD. Sustained Elevation of Pulsatile GH Secretion and IGF-I, IGFBP-3 and IGFBP-5 Concentration during 30-Day Continuous Infusion of GHRP-2 in Older Men and Women. J Clin Endocrinol Metab 2004; 89:2290-2300.

24. Veldhuis JD, Roemmich JN, Richmond EJ, Rogol AD, Lovejoy JC, Sheffield-Moore M, Mauras N, Bowers CY. Endocrine Control of Body Composition in Infancy, Childhood, and Puberty. Endoc Rev 2005; 26:114-146.

25. Laferrere B, Abraham C, Russell CD, Bowers CY. Growth Hormone Releasing Peptide -2(GHRP-2), Like Ghrelin, Increases Food Intake in Healthy Men. J Clin Endocrinol Metab 2005; 90:611-614.

26. Veldhuis JD, Anderson SM, Iranmanesh A, Bowers CY. Testosterone Blunts Feedback Inhibition of Growth Hormone Secretion by Experimentally Elevated Insulin-like Growth Factor-1 Concentration. J Clin Endocrinol Metab 2005; 90:1613-1617.

27. Erickson D, Keenan DM, Farhy L, Mielke K, Bowers CY, Veldhuis JD. Determinants of Dual Secretagogue Drive of Burst Like Growth Hormone Secretion in Premenopausal Women Studied Under a Selective estradiol Clamp. J Clin Endocrinol Metab 2005; 90:1741-1751.

28. Soares-Welsh C, Farhy L, Mielke KL, Mahmud FH, Miles JL, Bowers CY, Veldhuis JD. Complementary Secretagogue Pairs Unmask Prominent Gender-related Contrasts in Mechanisms of Growth Hormone Pulse Renewal in Young Adults. J Clin Endocrinol Metab 2005; 90:2225-2232.

29. Veldhuis JD, Iranmanesh A Bowers CY. Joint Mechanisms of Impaired GH Pulse Renewal in Aging Men. J Clin Endocrinol Metab 2005; 90:4177-4183.

30. Bowers CY. Octanoyl Ghrelin is Hypothalamic Rooted. Endocrinology 2005; 146:2508-2509.

31. Veldhuis JD, Keenan DM, Mielke K, Miles JM, Bowers CY. Supraphysiological Testosterone Supplementation in Healthy Older Men Drives GH and IGF-I Secretion without Potentiating Peptidyl Secretagogue Efficacy. Eur J Endocrinol 2005; 153:1-10.

32. Fintini D, Alba M, Schally AV, Bowers CY, Parlow AF, Salvatori R. Effects of Combined Long Term Treatment with a Growth Hormone-Releasing Hormone Analogue and a Growth Hormone Secretagogue in the Growth Hormone Releasing Hormone Knock Out Mouse. Neuroendocrinology 2005; 82(3-4):198-207.

33. Veldhuis JD, Roemmich JN, Richmond EJ, Bowers CY. Somatotropic and Gonadotropic Axes Linkages in Infancy, Childhood and the Puberty-Adult Transition. Endocr Rev 2006; 27(2):101-40.

34. Bowers CY, Chang J-K, Wu S, Linse KD, Hurley DL, Veldhuis JD. Biochemistry of Growth Hormone Secretagogue Molecules, In: Fat Loss, Wasting and Cachexia in Medicine, (Ed:) Schuster, M. and Mantovani, G. Springer Verlag, Chapter 5.7, 2006. p 219-234.

35. Laferrere B, Hart AB, Bowers CY. Obese Subjects Respond to the Stimulatory Effect of the Ghrelin Analogue Growth Hormone Releasing Peptide-2 (GHRP-2) on Food Intake. Obesity 2006; 14(6):1056-63.

36. Veldhuis JD, Iranmanesh A, Mielke K, Miles JM, Carpenter PC, Bowers CY. Ghrelin Potentiates Growth Hormone Secretion Driven by Putative Somatostatin Withdrawal and Resists Inhibition by Human Corticotropin-Releasing Hormone. J Clin Endocrinol Metab 2006; 91(6)2441-6.

37. Veldhuis JD, Keenan DM, Iranmanesh A, Mielke K, Miles JM, Bowers CY. Estradiol Potentiates Ghrelin-Stimulated Pulsatile GH Secretion in Postmenopausal Women. J Clin Endocrinol Metab 2006; 91(9):3559-65.

38. Farhy LS, Bowers CY, Veldhuis JD. Model-Projected Mechanistic Bases for Sex Differences in Growth-Hormone (GH) Regulation in the Human. Am J Regul Integr Comp Physiol 2007; 292(4):R1577-93.

39. Veldhuis JD, Keenan DM, Bowers CY. Estimation of the Size and Shape of GH Secretory Burst in Healthy Women Using a Physiological Estradiol Clamp and Variable-Waveform Deconvolution Model. Am J Physiol Regul Integr Comp Physiol. 2007; 293(3):R1013-21.

40. Veldhuis JD, Keenan DM, Bowers CY. Peripheral Estrogen Receptor-Alpha Selectivity Modulates the Waveform of GH Secretory Burst in Healthy Women. Am J Physiol Regul Integr Comp Physiol. 2007; 293(4):R1514-21.

41. Iranmanesh A, Carpenter PC, Mielke K, Bowers CY, Veldhuis JD. Putative Somatostatin Suppression Potentiates ACTH Secretion Driven by Ghrelin and Human Corticotropin-Releasing Hormone. J Clin Endocrinol Metab 2007; 92(9):3653-9.

42. Veldhuis JD, Cosma M, Erickson D, Paulo R, Mielke K, Farhy LS, Bowers CY. Tripartite Control of Growth Hormone Secretion in Women during Controlled Estradiol Repletion. J Clin Endocrinol Metab 2007; 92:2336-2345

43. Bowers CY, Laferrere B, Hurley D, Veldhuis JD. The Role of GHS and Ghrelin in Feeding and Body Composition. Metabolism and Obesity, Research and Clinical Applications (Ed) Patricia A. Donohoue, MD, Humana Press, Totowa, New Jersey 2008, p. 125-154.

44. Bowers CY, Merriam GR, Veldhuis JD. Validation of Growth-Hormone-Releasing Peptide-2 for the Diagnosis of Adult Growth Hormone Deficiency. Nat Clin Pract Endocrinol Metab 2008; 4(2):68-9.

45. Cosma M, Bailey J, Miles JM, Bowers CY, Veldhuis JD. Pituitary and/or Peripheral Estrogen-Receptor Alpha ER{alpha}) Regulated FSH Secretion Whereas Non-pituitary/peripheral/ER {alpha} Pathways Direct GH and Prolactin Secretion in Postmenopausal Women. J Clin Endocrinol Metab 2007; 93(3):951-8.

46. Paulo RC, Cosma M, Soares-Welch C, Bailey JN, Mielke KL, Miles JM, Bowers CY, Veldhuis JD. Gonadal Status and Body-Mass Index Jointly Determine GHRH/GHRP Synergy in Healthy Men. J Clin Endocrinol Metab 2008; 93(3):944-50.

47. Perboni S, Bowers CY, Kojima S, Asakawa A, Inui A. Growth Hormone Releasing Peptide 2 Reverses Anorexia Associated with Chemotherapy with 5-Fluoruracil in Colon Cancer Cell-Bearing Mice. World J Gastroenterology 2008; 14(41): 6303-05.

48. Paulo RC, Cosma M, Soares-Welch C, Bailey JN, Mielke KL, Miles JM, Bowers CY, Veldhuis JD. Gonadal Status and Body Mass Index Jointly Determine Growth Hormone (GH) Releasing Hormone/GH-Releasing Peptide Synergy in Healthy Men. J Clin Endocrinol Metab 2008; 93(3):944-50.

49. Bowers CY, Merriam GR, Veldhuis JD. Validation of Growth Hormone-Releasing Peptide 2 for the Diagnosis of Adult Growth Hormone Deficiency. Nat Clin Pract Endocrinol Metab 2008; 4(2):68-9.

50. Veldhuis JD, Reynolds GA, Iranmanesh A, Bowers CY. Twenty-Four Hour Continuous Ghrelin Infusion Augments Physiologically Pulsatile Nycthemeral and Entropic (feedback-regulated) Modes of Growth Hormone Secretion. J Clin Endocrinol Metab 2008; 93(9):3597-603.

51. Kok P, Paulo R, Cosma M, Mielke KL, Miles JM, Bowers CY, Veldhuis, JD. Estrogen Supplementation Selectively Enhances Hypothalamo-Pituitary Sensitivity to Ghrelin in Postmenopausal Women. J Clin Endocrinol Metab 2008; 93(10):4020-6.

52. Paulo R, Brundage R, Cosma M, Mielke KL, Bowers CY, Veldhuis JD. Estrogen Elevates the Peak Overnight Production Rate of Acylated Ghrelin. J Clin Endocrinol Metab 2008; 93(11):4440-7.

53. Veldhuis JD, Cosma M, Soares-Welch C, Paulo R, Miles JM, Bowers, CY. Aromatase and 5 a-Reductase Inhibition during an Exogenous Testosterone Clamp Unveils Selective Sex-Steroid Modulation of Somatostatin and Growth Hormone Secretagogue Actions in Healthy Older Men. J Clin Endocrinol Metab 2009; [Epub ahead of print] PMID   19088159.

Related Research Articles

<span class="mw-page-title-main">Growth hormone</span> Peptide hormone that stimulates growth, cell reproduction and cell regeneration

Growth hormone (GH) or somatotropin, also known as human growth hormone in its human form, is a peptide hormone that stimulates growth, cell reproduction, and cell regeneration in humans and other animals. It is thus important in human development. GH also stimulates production of IGF-1 and increases the concentration of glucose and free fatty acids. It is a type of mitogen which is specific only to the receptors on certain types of cells. GH is a 191-amino acid, single-chain polypeptide that is synthesized, stored and secreted by somatotropic cells within the lateral wings of the anterior pituitary gland.

<span class="mw-page-title-main">Cortistatin (neuropeptide)</span> Mammalian protein found in humans

Precortistatin is a protein that in humans is encoded by the CORT gene. The 105 amino acid residue human precortistatin in turn is cleaved into cortistatin-17 and cortistatin-29. Cortistatin-17 is the only active peptide derived from the precursor. Cortistatin is a neuropeptide that is expressed in inhibitory neurons of the cerebral cortex, and which has a strong structural similarity to somatostatin. Unlike somatostatin, when infused into the brain, it enhances slow-wave sleep. It binds to sites in the cortex, hippocampus and the amygdala.

<span class="mw-page-title-main">Arcuate nucleus</span>

The arcuate nucleus of the hypothalamus is an aggregation of neurons in the mediobasal hypothalamus, adjacent to the third ventricle and the median eminence. The arcuate nucleus includes several important and diverse populations of neurons that help mediate different neuroendocrine and physiological functions, including neuroendocrine neurons, centrally projecting neurons, and astrocytes. The populations of neurons found in the arcuate nucleus are based on the hormones they secrete or interact with and are responsible for hypothalamic function, such as regulating hormones released from the pituitary gland or secreting their own hormones. Neurons in this region are also responsible for integrating information and providing inputs to other nuclei in the hypothalamus or inputs to areas outside this region of the brain. These neurons, generated from the ventral part of the periventricular epithelium during embryonic development, locate dorsally in the hypothalamus, becoming part of the ventromedial hypothalamic region. The function of the arcuate nucleus relies on its diversity of neurons, but its central role is involved in homeostasis. The arcuate nucleus provides many physiological roles involved in feeding, metabolism, fertility, and cardiovascular regulation.

<span class="mw-page-title-main">Ghrelin</span> Peptide hormone involved in appetite regulation

Ghrelin is a hormone produced by enteroendocrine cells of the gastrointestinal tract, especially the stomach, and is often called a "hunger hormone" because it increases the drive to eat. Blood levels of ghrelin are highest before meals when hungry, returning to lower levels after mealtimes. Ghrelin may help prepare for food intake by increasing gastric motility and stimulating the secretion of gastric acid.

Neuroendocrinology is the branch of biology which studies the interaction between the nervous system and the endocrine system; i.e. how the brain regulates the hormonal activity in the body. The nervous and endocrine systems often act together in a process called neuroendocrine integration, to regulate the physiological processes of the human body. Neuroendocrinology arose from the recognition that the brain, especially the hypothalamus, controls secretion of pituitary gland hormones, and has subsequently expanded to investigate numerous interconnections of the endocrine and nervous systems.

Growth hormone–releasing hormone (GHRH), also known as somatocrinin or by several other names in its endogenous forms and as somatorelin (INN) in its pharmaceutical form, is a releasing hormone of growth hormone (GH). It is a 44-amino acid peptide hormone produced in the arcuate nucleus of the hypothalamus.

<span class="mw-page-title-main">Obestatin</span> Hormone that is produced in the stomach

Obestatin is a hormone that is produced in specialized epithelial cells of the stomach and small intestine of several animals including humans. Obestatin was originally identified as an anorectic peptide, but its effect on food intake remains controversial.

Somatostatinomas are a tumor of the delta cells of the endocrine pancreas that produces somatostatin. Increased levels of somatostatin inhibit pancreatic hormones and gastrointestinal hormones. Thus, somatostatinomas are associated with mild diabetes mellitus, steatorrhoea and gallstones, and achlorhydria. Somatostatinomas are commonly found in the head of pancreas. Only ten percent of somatostatinomas are functional tumours [9], and 60–70% of tumours are malignant. Nearly two-thirds of patients with malignant somatostatinomas will present with metastatic disease.

<span class="mw-page-title-main">Growth hormone secretagogue receptor</span> Protein-coding gene in the species Homo sapiens

Growth hormone secretagogue receptor(GHS-R), also known as ghrelin receptor, is a G protein-coupled receptor that binds growth hormone secretagogues (GHSs), such as ghrelin, the "hunger hormone". The role of GHS-R is thought to be in regulating energy homeostasis and body weight. In the brain, they are most highly expressed in the hypothalamus, specifically the ventromedial nucleus and arcuate nucleus. GSH-Rs are also expressed in other areas of the brain, including the ventral tegmental area, hippocampus, and substantia nigra. Outside the central nervous system, too, GSH-Rs are also found in the liver, in skeletal muscle, and even in the heart.

<span class="mw-page-title-main">GHRP-6</span> Chemical compound

Growth hormone-releasing peptide 6 (GHRP-6), also known as growth hormone-releasing hexapeptide, is one of several synthetic met-enkephalin analogues that include unnatural D-amino acids, were developed for their growth hormone-releasing activity and are called growth hormone secretagogues. They lack opioid activity but are potent stimulators of growth hormone (GH) release. These secretagogues are distinct from growth hormone releasing hormone (GHRH) in that they share no sequence relation and derive their function through activation of a completely different receptor. This receptor was originally called the growth hormone secretagogue receptor (GHSR), but due to subsequent discoveries, the hormone ghrelin is now considered the receptor's natural endogenous ligand, and it has been renamed as the ghrelin receptor. Therefore, these GHSR agonists act as synthetic ghrelin mimetics.

<span class="mw-page-title-main">Growth-hormone-releasing hormone receptor</span> Receptor protein that binds with somatcrinin

The growth-hormone-releasing hormone receptor (GHRHR) is a G-protein-coupled receptor that binds growth hormone-releasing hormone. The GHRHR activates a Gs protein that causes a cascade of cAMP via adenylate cyclase. GHRHR is distinct from the growth hormone secretagogue receptor, where growth hormone releasing peptides act to release growth hormone.

CJC-1295, also known as DAC:GRF, is a synthetic analogue of growth hormone-releasing hormone (GHRH) and a growth hormone secretagogue (GHS) which was developed by ConjuChem Biotechnologies. It is a modified form of GHRH (1-29) with improved pharmacokinetics, especially in regard to half-life.

<span class="mw-page-title-main">Ibutamoren</span> Experimental drug

Ibutamoren is a potent, long-acting, orally-active, selective, and non-peptide agonist of the ghrelin receptor and a growth hormone secretagogue, mimicking the growth hormone (GH)-stimulating action of the endogenous hormone ghrelin. It has been shown to increase the secretion of several hormones including GH and insulin-like growth factor 1 (IGF-1) and produces sustained increases in the plasma levels of these hormones without affecting cortisol levels.

Modified GRF (1-29) often abbreviated as mod GRF (1-29), originally known as tetrasubstituted GRF (1-29), is a term used to identify a 29 amino acid peptide analogue of growth-hormone-releasing hormone (GHRH), a releasing hormone of growth hormone (GH). It is a modified version of the shortest fully functional fragment of GHRH, often referred to as growth hormone releasing factor (1-29), and also known by its standardized name, sermorelin.

Growth hormone secretagogues or GH secretagogues (GHSs) are a class of drugs which act as secretagogues of growth hormone (GH). They include agonists of the ghrelin/growth hormone secretagogue receptor (GHSR), such as ghrelin (lenomorelin), pralmorelin (GHRP-2), GHRP-6, examorelin (hexarelin), ipamorelin, and ibutamoren (MK-677), and agonists of the growth hormone-releasing hormone receptor (GHRHR), such as growth hormone-releasing hormone, CJC-1295, sermorelin, and tesamorelin.

<span class="mw-page-title-main">Pralmorelin</span> Chemical compound

Pralmorelin (INN), also known as pralmorelin hydrochloride (JAN) and pralmorelin dihydrochloride (USAN), as well as, notably, growth hormone-releasing peptide 2 (GHRP-2), is a growth hormone secretagogue (GHS) used as a diagnostic agent that is marketed by Kaken Pharmaceutical in Japan in a single-dose formulation for the assessment of growth hormone deficiency (GHD).

<span class="mw-page-title-main">Ipamorelin</span> Peptide selective agonist of the ghrelin/growth hormone secretagogue receptor

Ipamorelin (INN) (developmental code name NNC 26-0161) is a peptide selective agonist of the ghrelin/growth hormone secretagogue receptor (GHS) and a growth hormone secretagogue. It is a pentapeptide with the amino acid sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 that was derived from GHRP-1.

<span class="mw-page-title-main">Examorelin</span> Chemical compound

Examorelin (INN) (developmental code names EP-23905, MF-6003), also known as hexarelin, is a potent, synthetic, peptidic, orally-active, centrally-penetrant, and highly selective agonist of the ghrelin/growth hormone secretagogue receptor (GHSR) and a growth hormone secretagogue which was developed by Mediolanum Farmaceutici. It is a hexapeptide with the amino acid sequence His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2 which was derived from GHRP-6. These GH-releasing peptides have no sequence similarity to ghrelin, but mimic ghrelin by acting as agonists at the ghrelin receptor.

<span class="mw-page-title-main">Serghei Tarnovschi</span> Ukrainian-Moldovan canoeist

Serghei Tarnovschi is a Moldovan-Ukrainian sprint canoeist. He competed at the 2020 Summer Olympics, in Men's C-1 1000 m, winning a bronze medal.

<span class="mw-page-title-main">Hypothalamic–pituitary–somatotropic axis</span>

The hypothalamic–pituitary–somatotropic axis, or hypothalamic–pituitary–somatic axis, also known as the hypothalamic–pituitary–growth axis, is a hypothalamic–pituitary axis which includes the secretion of growth hormone from the somatotropes of the pituitary gland into the circulation and the subsequent stimulation of insulin-like growth factor 1 production by GH in tissues such as, namely, the liver. Other hypothalamic–pituitary hormones such as growth hormone-releasing hormone, growth hormone-inhibiting hormone, and ghrelin (GHS) are involved in the control of GH secretion from the pituitary gland. The HPS axis is involved in postnatal human growth. Individuals with growth hormone deficiency or Laron syndrome show symptoms like short stature, dwarfism and obesity, but are also protected from some forms of cancer. Conversely, acromegaly and gigantism are conditions of GH and IGF-1 excess usually due to a pituitary tumor, and are characterized by overgrowth and tall stature.

References

[1] [2] [3] [4] [5] [6] [7] [8]

  1. ↑ "Ghrelin, appetite, and gastric motility: the emerging role of the stomach as an endocrine organ".
  2. ↑ "Grehlin - A New Obesity Related Peptide". Archived from the original on 2011-07-17. Retrieved 2010-03-22.
  3. ↑ "Unnatural Growth Hormone-Releasing Peptide Begets Natural Ghrelin".
  4. ↑ "Octanoyl Ghrelin Is Hypothalamic Rooted".
  5. ↑ "The Journal Of Clinical Endocrinology & Metabolism".
  6. ↑ "Laureate Award Recipients - Louisiana - ACP". www.acponline.org.
  7. ↑ "Find A Biomed Experts". Archived from the original on 2012-02-23. Retrieved 2010-03-22.
  8. ↑ Bowers, Cyril Y.; Chang, Jaw-Kang; Wu, Shaoxing; Linse, Klaus D.; Hurley, David L.; Veldhuis, Johannes D. (29 January 2019). Mantovani, Giovanni; Anker, Stefan D.; Inui, Akio; Morley, John E.; Fanelli, Filippo Rossi; Scevola, Daniele; Schuster, Michael W.; Yeh, Shing-Shing (eds.). Cachexia and Wasting: A Modern Approach. Springer Milan. pp. 219–234. doi:10.1007/978-88-470-0552-5_23.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.